Biomarin Pharmaceutical (BMRN) Equity Average (2010 - 2026)

Biomarin Pharmaceutical has disclosed Equity Average across 17 years of filings, most recently posting $6.1 billion for Q1 2026.

• Quarterly Equity Average rose 7.4% year-over-year to $6.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.1 billion (up 7.4% YoY) and the FY2025 annual result came in at $5.9 billion, up 10.7% from the prior year.
• Equity Average climbed to $6.1 billion in Q1 2026, from $6.1 billion in the prior quarter.
• Over five years, Equity Average peaked at $6.1 billion in Q1 2026 and troughed at $4.3 billion in Q1 2022.
• A 5-year average of $5.2 billion and a median of $5.0 billion in 2024 frame the typical range for Equity Average.
• Annual changes were most pronounced in 2022 — Equity Average rose 4.71% — and 2025, when it advanced 14.22%.
• Tracing BMRN's Equity Average over 5 years: stood at $4.6 billion in 2022, then gained by 7.38% to $4.9 billion in 2023, then increased by 12.42% to $5.5 billion in 2024, then increased by 9.69% to $6.1 billion in 2025, then grew by 1.28% to $6.1 billion in 2026.
• Business Quant data shows BMRN's Equity Average at $6.1 billion in Q1 2026, $6.1 billion in Q4 2025, and $6.0 billion in Q3 2025.